Discovery of tyrosine-based potent and selective melanocortin-1 receptor small-molecule agonists with anti-inflammatory properties

Journal of Medicinal Chemistry

Volumn 46, Issue 7, 2003, Pages 1123-1126

  Herpin, Timothy F ^a   Yu, Guixue ^a   Carlson, Kenneth E ^a   Morton, George C ^a   Wu, Ximao ^a   Kang, Liya ^a   Tuerdi, Huji ^a   Khanna, Ashish ^a   Tokarski, John S ^a   Lawrence, R Michael ^a   Macor, John E ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; G PROTEIN COUPLED RECEPTOR; MELANOCORTIN 1 RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TYROSINE; TYROSINE DERIVATIVE;

ANIMAL CELL; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING AFFINITY; CHO CELL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; INFLAMMATION; MOUSE; NONHUMAN; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ACUTE DISEASE; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COMBINATORIAL CHEMISTRY TECHNIQUES; HUMANS; INFLAMMATION; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; RECEPTORS, CORTICOTROPIN; RECEPTORS, MELANOCORTIN; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; TYROSINE;

EID: 0037468906     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm025600i     Document Type: Article

References (55)

1. (a) The Melanocortin Receptors; Cone, R. D., Ed.; Humana Press Inc.: Totwa, NJ, 2000.
2. (b) Wikberg, J. E. S.; Muceniece, R.; Mandrika, I.; Prusis, P.; Lindblom, J.; Post, CI.; Skottner, A. New aspects on the melanocortins and their receptors. Pharm. Res. 2000, 42, 393-420.
3. (c) MacNeil, D. J.; Howard, A. D.; Guan, X.; Fong, T. M.; Nargund, R. P.; Bednarek, M. A.; Goulet, M. T.; Weinberg, D. H.; Strack, A. M.; Marsh, D. J.; Chen, H. Y.; Shen, C.-P.; Chen, A. S.; Rosenblum, C. I.; MacNeil, T.; Tota, M.; MacIntyre, E. D.; Van der Ploeg, L. H. T. The role of melanocortins in body weight regulation: opportunities for the treatment of obesity. Eur. J. Pharmacol. 2002, 440, 141-157.
4. (a) Lu, D.; Haskell-Luevano, C.; Vage, D. I.; Cone, R. D. The Melanocortin-1 Receptor. In The Melanocortin Receptors; Cone, R. D., Ed.; Humana Press: Totwa, NJ, 2000; pp 309-340.
5. (b) Healy, E.; Birch-Machin, M.; Rees, J. L. The Human Melanocortin-1 Receptor. In The Melanocortin Receptors; Cone, R. D., Ed.; Humana Press: Totwa, NJ, 2000; pp 341-360.
6. Clark, A. J. L. The Melanocortin-2 Receptor in Normal Adrenocortical Function and Familial Adrenocoricotropic Hormone Resistance. In The Melanocortin Receptors; Cone, R. D., Ed., Humana Press: Totwa, NJ, 2000; pp 361-384.
7. (a) Kesterson, R. A. The Melanocortin-3 Receptor. In The Melanocortin Receptors; Cone, R. D., Ed.; Humana Press: Totwa, NJ, 2000; pp 385-404.
8. (b) Lee, Y.-S.; Poh, L. K.-S.; Loke, K.-Y. A novel melanocortin 3 receptor gene (MC-3R) mutation associated with severe obesity. J. Clin. Endocrinol. Metab. 2002, 87, 1423-1426.
9. (c) Chen, A. S.; Marsh, D. J.; Trumbauer, M. E.; Frazier, E. G.; Guan, X.-M.; Yu, H.; Rosenblum, C. I.; Vongs, A.; Feng, Y.; Cao, L.; Metzger, J. M.; Strack, A. M.; Camacho, R. E.; Mellin, T. N.; Nunes, C. N.; Min, W.; Fisher, J.; Gopal-Truter, S.; MacIntyre, D. E.; Chen, H. Y.; Van der Ploeg, L. H. T. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat. Genet. 2000, 26, 97-102.
10. (d) Butler, A. A.; Kesterson, R. A.; Khong, K.; Cullen, M.-J.; Pelleymounter, M.-A.; Dekoning, J.; Baetscher, M.; Cone, R. D. A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. Endocrinology 2000, 141, 3518-3521.
11. (e) Getting, S. J.; Allcock, G. H.; Flower, R.; Perretti, M. Natural and synthetic agonists of the melanocortin receptor type 3 possess anti-inflammatory properties. J. Leukocyte Biol. 2001, 69, 98-104.
12. (a) Cone, R. D. The Melanocortin-4 Receptor. In The Melanocortin Receptors; Cone, R. D., Ed.; Humana Press: Totwa, NJ, 2000; pp 405-448.
13. (b) Marie, L.; Miura, G. I.; Marsh, D. J.; Yagaloff, K.; Palmiter, R. D. A metabolic defect promotes obesity in mice lacking melanocortin-4 receptors. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 12339-12344.
14. (c) Benoit, S. C.; Schwartz, M. W.; Lachey, J. L.; Hagan, M. M.; Rushing, P. A.; Blake, K. A.; Yagaloff, K. A.; Kurylko, G.; Franco, L.; Danhoo, W.; Seeley, R. J. A novel selective melanocortin-4 receptor agonist reduces food intake in rats and mice without producing aversive consequences. J. Neurosci. 2000, 20, 3442-3448.
15. (d) Van der Ploeg, L. H. T.; Martin, W. J.; Howard, A. D.; Nargund, R. P.; Austin, C. P.; Guan, X.; Drisko, J.; Cashen, D.; Sebhat, I.; Patchett, A. A.; Figueroa, D. J.; DiLella, A. G.; Connolly, B. M.; Weinberg, D. H.; Tan, C. P.; Palyha, O. C.; Pong, S.-S.; MacNeil, T.; Rosenblum, C.; Vongs, A.; Tang, R.; Yu, H.; Sailer, A. W.; Fong, T. M.; Huang, C.; Tota, M. R.; Chang, R. S.; Stearns, R.; Tamvakopoulos, C.; Christ, G.; Drazen, D. L.; Spar, B. D.; Nelson, R. J.; MacIntyre, D. E. A role for the melanocortin 4 receptor in sexual function. Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 11381-11386.
16. (e) Sebhat, I. K.; Martin, W. J.; Ye, Z.; Barakat, K.; Mosley, R. T.; Johnston, D. B. R.; Bakshi, R.; Palucki, B.; Weinberg, D. H.; MacNeil, T.; Kalyani, R. N.; Tang, R.; Stearns, R. A.; Miller, R. R.; Tamvakopoulos, C.; Strack, A. M.; McGowan, E.; Cashen, D. E.; Drisko, J. E.; Hom, G. J.; Howard, A. D.; MacIntyre, D. E.; van der Ploeg, L. H. T.; Patchett, A. A.; Nargund, R. P. Design and pharmacology of N-[(3R)-1,2,3,4-tetrahydroisoquinolinium-3-ylcarbonyl]-(1R)-1-(4- chlorobenzyl)-2-[4-cyclohexyl-4-(1H-1,2,4-triazol-1-ylmethyl) piperidin-1-yl]-2-oxoethylamine (1), a potent, selective, melanocortin subtype-4 receptor agonist. J. Med. Chem. 2002, 45, 4589-4593.
17. (a) Chen, W. The Melanocortin-5 Receptor. In The Melanocortin Receptors; Cone, R. D., Ed.; Humana Press: Totwa, NJ, 2000; pp 449-474.
18. (b) Chen, W.; Kelly, M. A.; Opitz-Araya, X.; Thomas, R. E.; Low, M. J.; Cone, R. D. Exocrine Gland Dysfunction in MC5-R Deficient Mice: Evidence for Coordinated Regulation of Exocrine Glands Functions by Melanocortin Peptides. Cell 1997, 91, 789-798.
19. Eberle, A. N. Proopiomelanocortin and the Melanocortin Peptides. In The Melanocortin Receptors; Cone, R. D., Ed.; Humana Press: Totwa, NJ, 2000; pp 3-68.
20. Haskell-Luevano, C.; Sawyer, T. K.; Hendrata, S.; North, C.; Panahinia, L.; Stum, M.; Staples, D. J.; Castrucci, A. M.; Hadley, M. E.; Hruby, V. J. Truncation studies of α-melanotropin peptides identify tripeptide analogs exhibiting prolonged agonist bioactivity. Peptides 1996, 17, 995-1002.
21. (a) Lu, D.; Willard, D.; Patel, I. R.; Kadwell, S.; Overton, L.; Kost, T.; Luther, M.; Chen, W.; Yowchik, R. P.; Wilkison, W. O.; Cone, R. D. Agouti Protein is an Antagonist of the Melanocyte-Stimulating-Hormone Receptor. Nature 1994, 371, 799-802.
22. (b) Shutter, J. R.; Graham, M.; Kinsey, A. C.; Scully, S.; Luthy, R.; Stark, K. L. Hypothalamic Expression of ART, a Novel Gene Related to Agouti, Is Up-Regulated in Obese and Diabetic Mutant Mice. Genes Dev. 1997, 11, 593-602.
23. (c) Ollmann, M. M.; Wilson, B. D.; Yang, Y.-K.; Kerns, J. A.; Chen, Y.; Gantz, I.; Barsh, G. S. Antagonism of Central Melanocortin Receptors in Vitro and in Vivo by Agouti-Related Protein. Science 1997, 278, 135-138.
24. (a) Sawyer, T. K.; Sanfillippo, P. J.; Hruby, V. J.; Engel, M. H.; Heward, C. B.; Burnett, J. B.; Hadley, M. E. 4-Norleucine, 7-D-Phenylalanine-R-Melanocyte-Stimulating Hormone: A Highly Potent R-Melanotropin with Ultra Long Biological Activity. Proc. Natl. Acad. Sci. U.S.A. 1980, 77, 5754-5758.
25. (b) Haskell-Luevano, C.; Holder, J. R.; Monck, E. K.; Bauzo, R. M. Characterization of melanocortin NDP-MSH agonist peptide fragments at the mouse central and peripheral melanocortin receptors. J. Med. Chem. 2001, 44, 2247-2252.
26. (a) Al-Obeidi, F.; Castrucci, A. M.; Hadley, M. E.; Hruby, V. J. Potent and Prolonged Acting Cyclic Lactam Analogues of R- Melanotropin: Design Based on Molecular Dynamics. J. Med. Chem. 1989, 32, 2555-2561.
27. (b) Haskell-Luevano, C.; Miwa, H.; Dickinson, C.; Hadley, M. E.; Hruby, V. J.; Yamada, T.; Gantz, I. Characterizations of the Unusual Dissociation Properties of Melanotropin Peptides from the Melanocortin Receptor, hMC1R. J. Med. Chem. 1996, 39, 432-435.
28. Wessells, H.; Fuciarelli, K.; Hansen, J.; Hadley, M. E.; Hruby, V. J.; Dorr, R.; Levine, N. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J. Urol. 1998, 160, 389-393.
29. (a) Hruby, V. J.; Lu, D.; Sharma, S. D.; Castrucci, A. L.; Kesterson, R. A.; al-Obeidi, F. A.; Hadley, M. E.; Cone, R. D. Cyclic lactam a-melanotropin analogs of Ac-Nle4-cyclo[Asp5,D- Phe7,Lys 10]-α-melanocyte-stimulating hormone-(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. J. Med. Chem. 1995, 38, 3454-3461.
30. (b) Schioth, H. B.; Muceniece, R.; Mutulis, F.; Bouifrouri, A. A., Mutule, I.; Wikberg, J. E. Further pharmacological characterization of the selective melanocortin 4 receptor antagonist HS014: comparison with SHU9119. Neuropeptides 1999, 33, 191-196.
31. (c) Yang, Y.; Chen, M.; Lai, Y.; Gantz, I.; Georgeson, K. E.; Harmon, C. M. Molecular determinants of human melanocortin-4 receptor responsible for antagonist SHU9119 selective activity. J. Biol. Chem. 2002, 277, 20328-20335.
32. (a) Suto, M. J.; Girten, B. E.; Houghten, R. A.; Loullis, C. C.; Tuttle, R. R. Preparation of peptide cytokine restraining agents. Patent WO 9513086, 1995.
33. (b) Loullis, C.; Basu, A.; Garcia, A.; Frazer, J.; Robison, A.; Tuttle, R. Rising single dose safety and tolerance of HP 228 in normal male volunteers. Pharm. Res. 1995, 12, S392.
34. (c) Weinger, M. B.; Chaplan, S. R.; Girten, B. E.; Powell, F. L. The respiratory effects of the cytokine regulating agent HP 228 alone and in combination with morphine in human volunteers. Pharmacol. Biochem. Behav. 1998, 59, 759-766.
35. Andersson, P. M.; Boman, A.; Seifert, E.; Skottner, A.; Lundstedt, T. Ligands to the melanocortin receptors. Expert Opin. Ther. Pat. 2001, 11, 1583-1592.
36. (a) Patchett, A. A.; Van der Ploeg, L. H. T.; Ye, Z.; Bakshi, R. K.; Nargund, R. P.; Palucki, B. L. Spiropiperidine derivatives as melanocortin receptoragonists. Patent WO9964002, 1999.
37. (b) Bakshi, R. K.; Barakat, K. J.; Nargund, R. P.; Palucki, B. L.; Patchett, A. A.; Sebhat, I.; Ye, Z.; Van Der Ploeg, L. H. T. Preparation of piperidine amino acid derivatives as melanocortin-4 receptor agonists. Patent WO0074679, 2000.
38. (c) Bakshi, R. K.; Barakat, K. J.; Lai, Y.; Nargund, R. P.; Palucki, B. L.; Park, M. K.; Patchett, A. A.; Sebhat, I.; Ye, Z. Preparation of substituted piperidines as melanocortin receptor agonists. Patent WO0215909, 2002.
39. (a) Basu, A.; Gahman, T. C.; Girten, B. E.; Griffith, M. C.; Hecht, C. C.; Kiely, J. S.; Slivka, S. R.; Dines, K. S. Isoquinoline compound melanocortin receptor ligands. Patent WO 9955679, 1999.
40. (b) Dines, K. C.; Gahman, T. C.; Girten, B. E.; Hitchin, D. L.; Holme, K. R.; Lang, H.; Slivka, S. R.; Watson-Straughan, K. J.; Tuttle, R. R.; Pei, Y. Melanocortin receptor-3 ligands to treat sexual dysfunction. Patent WO0105401, 2001.
41. (c) Lundstedt, T.; Skottner, A.; Seifert, E.; Starchenkov, I.; Kalvins, I. Preparation of aromatic amides useful as melanocortin receptor agonists and antagonists. Patent WO0155109, 2001.
42. (d) Lundstedt, T.; Skottner, A.; Seifert, E.; Andersson, P.; Kaulina, L.; Dikovskaya, K.; Mutule, I.; Mutulis, F.; Wikberg, J.; Starchenkov, I.; Kreicberga, J. Preparation of aromatic amines and amides useful as melanocortin receptor agonists and antagonists. Patent WO0155107, 2001.
43. (a) Haskell-Luevano, C.; Rosenquist, A.; Souers, A.; Khong, K. C.; Ellman, J. A.; Cone, R. D. Compounds that activate the mouse melanocortin-1 receptor identified by screening a small molecule library based upon the β-turn. J. Med. Chem. 1999, 42, 4380-4387.
44. (b) Haskell-Luevano, C.; Rosenquist, A.; Souers, A.; Khong, K. C.; Ellman, J. A.; Cone, R. D. Identification of melanocortin-1 receptor selective small molecule agonists. In Peptides for the New Millennium, Proceedings of the 16th American Peptide Symposium, Minneapolis, MN, June 26-July 1, 1999; Fields, G. B., Tam, J. P., Barany, G., Eds.; Klewer Academic: Dordrecht, 2000, pp 243-244.
45. (b) Haskell-Luevano, C.; Rosenquist, A.; Souers, A.; Khong, K. C.; Ellman, J. A.; Cone, R. D. Identification of melanocortin-1 receptor selective small molecule agonists. In Peptides for the New Millennium, Proceedings of the 16th American Peptide Symposium, Minneapolis, MN, June 26-July 1, 1999; Fields, G. B., Tam, J. P., Barany, G., Eds.; Klewer Academic: Dordrecht, 2000, pp 243-244.
46. (c) Bondebjerg, J.; Xiang, Z.; Bauzo, R. M.; Haskell -Luevano, C.; Meldal, M. A Solid-Phase Approach to Mouse Melanocortin Receptor Agonists Derived from a Novel Thioether Cyclized Peptidomimetic Scaffold. J. Am. Chem. Soc. 2002, 124, 11046-11055.
47. Lipton, J. M.; Catania, A. Anti-inflammatory actions of the neuroimmunomodulator α-MSH. Immunol. Today 1997, 18, 140-145.
48. (a) Bhardwaj, R.; Becher, E.; Mahnke, K.; Hartmeyer, M.; Schwarz, T.; Scholzen, T.; Luger, T. A. Evidence for the differential expression of the functional α-MSH receptor MC-1 on human monocytes. J. Immunol. 1997, 158, 3378-3384.
49. (b) Manna, S. K.; Aggarwal, B. B. α-MSH inhibits NF-kB activation induced by various inflammatory agents. J. Immunol. 1998, 161, 2873-2880.
50. (c) Rajora, N.; Ceriani, G.; Catania, A.; Star, R. A.; Murphy, M. T.; Lipton, J. M. α-MSH production, receptors, and influence on neopterin in a human monocyte/macrophage cell line. J. Leukocyte Biol. 1996, 59, 248-253.
51. (a) Chiao, H.; Kohda, Y.; McLeroy, P.; Craig, L.; Housini, I.; Star, R. A. α-MSH protects against renal injury after ischemia in mice and rats. J. Clin. Invest. 1997, 99, 1165-1172.
52. (b) Rajora, N.; Boccoli, G.; Catania, A.; Lipton, J. M. α-MSH modulates experimental inflammatory bowel disease. Peptides 1997, 18, 381-385.
53. Szardenings, M.; Muceniece, R.; Mutule, I.; Mutulis, F.; Wikberg, J. E. New highly specific agonistic peptides for human melanocortin MC(1) receptor. Peptides 2000, 21, 239-243.
54. Cone, R. D.; Lu, D.; Koppula, S.; Vage, D. I.; Klungland, H.; Boston, B.; Chen, W.; Orth, D. N.; Pouton, C.; Kesterson, R. A. The Melanocortin Receptors: Agonists, Antagonists, and the Hormonal Control of Pigmentation. Recent Prog. Horm. Res. 1996, 51, 287-317.
55. Gonindard, C.; Goigoux, C.; Hollande, E.; D'Hinterland, L. D. The administration of an alpha-MSH analogue reduced the serum release of IL-1alpha and TNF-alpha induced by the injection of a sublethal dose of lipopolysaccharides in the BALB/c mouse. Pigm. Cell Res. 1996, 9, 148-153.